Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer

Zhen Zhang, Robert C. Bast, Yinhua Yu, Jinong Li, Lori J. Sokoll, Alex J. Rai, Jason M. Rosenzweig, Bonnie Cameron, Young Y. Wang, Xiao Ying Meng, Andrew Berchuck, Carolien Van Haaften-Day, Neville F. Hacker, Henk W A De Bruijn, Ate G J Van Der Zee, Ian J. Jacobs, Eric T. Fung, Daniel W. Chan

    Research output: Contribution to journalArticlepeer-review


    Early detection remains the most promising approach to improve long-term survival of patients with ovarian cancer. In a five-center case-control study, serum proteomic expressions were analyzed on 153 patients with invasive epithelial ovarian cancer, 42 with other ovarian cancers, 166 with benign pelvic masses, and 142 healthy women. Data from patients with early stage ovarian cancer and healthy women at two centers were analyzed independently and the results cross-validated to discover potential biomarkers. The results were validated using the samples from two of the remaining centers. After protein identification, biomarkers for which an immunoassay was available were tested on samples from the fifth center, which included 41 healthy women, 41 patients with ovarian cancer, and 20 each with breast, colon, and prostate cancers. Three biomarkers were identified as follows: (a) apolipoprotein A1 (down-regulated in cancer); (b) a truncated form of transthyretin (down-regulated); and (c) a cleavage fragment of inter-a-trypsin inhibitor heavy chain H4 (up-regulated). In independent validation to detect early stage invasive epithelial ovarian cancer from healthy controls, the sensitivity of a multivariate model combining the three biomarkers and CA125 [74% (95% CI, 52-90%)] was higher than that of CA125 alone [65% (95% CI, 43-84%)] at a matched specificity of 97% (95% CI, 89-100%). When compared at a fixed sensitivity of 83% (95% CI, 61-95%), the specificity of the model [94% (95% CI, 85-98%)] was significantly better than that of CA125 alone [52% (95% CI, 39-65%)]. These biomarkers demonstrated the potential to improve the detection of early stage ovarian cancer.
    Original languageEnglish
    Pages (from-to)5882-5890
    Number of pages8
    JournalCancer Research
    Issue number16
    Publication statusPublished - 15 Aug 2004


    Dive into the research topics of 'Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer'. Together they form a unique fingerprint.

    Cite this